Dr Jenny Bailey Cooper has spent her career to date working in the field of gut health. She has a PhD in gastrointestinal immunology and 18 years’ research experience in gastrointestinal disease. Jenny has a keen interest in intestinal inflammation, particularly mucosal barrier function and novel therapeutics to disrupt inflammatory pathways. In 2019 Jenny became Co-founder and Chief Executive Officer of Ferryx. She has been responsible for the development of Ferryx's proprietary products since their early stages and has led commercialisation over the last four years. Jenny has led Ferryx through investment rounds, successful grant funding, and into revenue generation via launch of Ferryx's first product, Ferrocalm, in December 2022.